By proceeding, you agree to our Terms of Use and Privacy Policy.
CHI’s Sixth Annual Immuno-Oncology Summit Europe returns to London’s Canary Wharf for three packed days of science and technology, discussion and networking, with coverage of recent advances in the development of promising immuno-oncology treatments.
Learn about targeting the tumor microenvironment, immuno-oncology therapeutic development and bi-specific and multi-specific antibody therapeutics.
Discover insights relating to impact of TCB treatment/ enhancing myeloid activity and overcoming checkpoint resistance and immune stimulation.
Connect with industry experts and speakers like Catherine Alix-Panabières, Robert Arathoon, Marina Bacac, Gavin M Bendle, Mark S Cragg and others.
15-17 April 2024
Join us at the Festival of Biologics USA 2024, the most exciting biologics event in America! Taking place from April 15 to 17, 2024, at the renowned San Diego Convention Center, this three-day event will cover the entire journey of biologic drug deve
Event Started
USA
Paid
San Diego
18-19 April 2024
Join us at the MarketsandMarkets High Potent Medicines Conference, taking place on 19th - 20th October 2023, in Boston, USA. This groundbreaking conference is designed to address the emerging trends and challenges in the high potent medicines market.
Starts in 2 days
Boston
Cambridge Healthtech Institute – Your Life Science Network Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.
Reaction Biology provides pre-clinical drug discovery solutions as your trusted partner.
The future of immune medicine holds promise for lasting and durable impact on many diseases; our high resolution systems are powering the development and further personalization of these curative medicines.
LUMICKS is the leading supplier of Dynamic Single-Molecule and Cell Avidity analysis instruments.
Biointron is a leading high throughput recombinant antibody/protein expression provider. From gene sequence to purified antibodies, it just takes 2 weeks.
Cerba Research is the merge of Barc Lab, Histalim and Cerba Xpert. All 3 entities are part of the Cerba HealthCare group and have decided to join forces under one name.
Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.